A Study to Evaluate Safety, Tolerability, & Immunogenicity of Multiple Formulations of BNT162b2 Against COVID-19 in Healthy Adults

PHASE3CompletedINTERVENTIONAL
Enrollment

629

Participants

Timeline

Start Date

April 1, 2021

Primary Completion Date

December 1, 2021

Study Completion Date

December 2, 2021

Conditions
SARS-CoV-2 InfectionCOVID-19
Interventions
BIOLOGICAL

BNT162b2

Intramuscular injection

Trial Locations (21)

28401

Accellacare (formerly PMG Research of Wilmington, LLC), Wilmington

30281

Clinical Research Atlanta, Stockbridge

32256

Clinical Neuroscience Solutions, Inc. dba CNS Healthcare, Jacksonville

32801

Clinical Neuroscience Solutions, Orlando

33012

Indago Research & Health Center, Inc, Hialeah

33024

Research Centers of America ( Hollywood ), Hollywood

40004

Kentucky Pediatric/ Adult Research, Bardstown

43213

Aventiv Research Inc, Columbus

68134

Meridian Clinical Research, LLC, Omaha

77081

Texas Center for Drug Development, Inc., Houston

77375

DM Clinical Research (Administrative and Storage Office only), Tomball

Martin Diagnostic Clinic, Tomball

77555

University of Texas Medical Branch, Galveston

78705

Benchmark Research, Austin

83646

Solaris Clinical Research, Meridian

84109

J. Lewis Research, Inc. / Foothill Family Clinic, Salt Lake City

84121

J. Lewis Research, Inc. / Foothill Family Clinic South, Salt Lake City

92801

Anaheim Clinical Trials, LLC, Anaheim

94598

Diablo Clinical Research, Inc., Walnut Creek

96814

East-West Medical Research Institute, Honolulu

08869

Amici Clinical Research LLC, Raritan

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

BioNTech SE

INDUSTRY

NCT04816669 - A Study to Evaluate Safety, Tolerability, & Immunogenicity of Multiple Formulations of BNT162b2 Against COVID-19 in Healthy Adults | Biotech Hunter | Biotech Hunter